Negative in Ames, in vitro chromosome aberration, mouse lymphoma and mouse and rat micronucleus assays
“Tapinarof was not mutagenic or clastogenic in the Ames bacterial reverse mutation assay, the in vitro mammalian chromosome aberration test, and the in vitro mouse lymphoma assay. Tapinarof was not genotoxic in two in vivo micronucleus assays in mice and rats.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Carcinogenicity
Dermal mouse (98-102 weeks) and subcutaneous rat (females, 83 weeks): no drug-related neoplasms
“No drug-related neoplasms were noted in mice after 98 (females) to 102 (males) weeks of daily topical administration at doses up to 3% tapinarof cream (44 times the MRHD based on AUC comparisons). No drug-related neoplasms were noted in female rats after 83 weeks of daily subcutaneous administration at doses up to 1 mg/kg/day tapinarof (9 times the MRHD based on AUC comparisons).”
Rat PPND: decreased pup survival and viability at ≥6 mg/kg/day; NOAEL 1 mg/kg/day
“There were test article-related decreases in F1 pup survival and viability at ≥6 mg/kg/day that resulted in reduced litter sizes and decreased pup weights. The NOAEL was 1 mg/kg/day for tapinarof effects on prenatal and postnatal development of the offspring in rats.”
✓ VerifiedFDA multi-discipline review, p. 31Source ↗
“Tapinarof inhibited hERG channel tail current in a concentration-dependent manner. The IC25, IC50 and IC75 values were estimated to be 1.72, 4.02, and 9.37 μM, respectively.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative